PMD-026

DRUG2 trials

Sponsors

Phoenix Molecular Designs, Washington University School of Medicine

Conditions

Metastatic Breast CancerMyelofibrosis

Phase 1

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Active, not recruitingNCT04115306

Phoenix Molecular DesignsMetastatic Breast Cancer

Start: 2019-11-14End: 2026-12-01Target: 61Updated: 2026-07-16

Therapeutic RSK1 Targeting in Myelofibrosis

RecruitingNCT07379125

Washington University School of MedicineMyelofibrosis

Start: 2026-05-20End: 2028-12-31Target: 18Updated: 2026-05-22

Related Papers

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis

Leukemia2026-06-30

Abstract PS1-08-15: Dauntless-1: A Phase 2 Clinical Trial to Evaluate PMD-026, a First-in-Class Pan-RSK Inhibitor, Combined with Fulvestrant to Overcome Resistance to CDK4/6 Inhibitors in Advanced or Metastatic HR+/HER2- Breast Cancer

Clinical Cancer Research2026-02-17

Abstract P4-08-27: PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models

Clinical Cancer Research2025-06-13

Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.

Journal of Clinical Oncology2025-05-28

RSK1 Is an Exploitable Dependency in Myeloid Malignancies

Blood2023-11-022 citations

Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor

Cancer Research2023-03-012 citations

Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients

Cancer Research2022-02-15

First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.

Journal of Clinical Oncology2021-05-2024 citations

Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients

Cancer Research2021-02-151 citations

First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.

Journal of Clinical Oncology2020-05-201 citations